MétaCan
Menu
Back to cohort
Record W4395063849 · doi:10.1016/j.cjco.2024.03.007

Safety of Continuing Trastuzumab for Mild Cardiotoxicity: A Cardiovascular Magnetic Resonance Imaging Study

2024· article· en· W4395063849 on OpenAlexafffund
Sivisan Suntheralingam, Nichanan Osataphan, Coleen Power, Chun‐Po Steve Fan, Husam Abdel‐Qadir, Eitan Amir, Paaladinesh Thavendiranathan

Bibliographic record

VenueCJC Open · 2024
Typearticle
Languageen
FieldMedicine
TopicChemotherapy-induced cardiotoxicity and mitigation
Canadian institutionsPrincess Margaret Cancer CentreUniversity Health NetworkUniversity of TorontoToronto General HospitalWomen's College HospitalTed Rogers Centre for Heart Research
FundersCanadian Institutes of Health ResearchCanadian Cancer Society
KeywordsCardiotoxicityTrastuzumabMagnetic resonance imagingMedicineCardiac magnetic resonanceInternal medicineCardiologyRadiologyCancerToxicityBreast cancer

Abstract

fetched live from OpenAlex

The safety of continuing human epidermal growth factor receptor 2 (HER2)–targeted therapy in women with mild cardiotoxicity remains unclear. We performed a retrospective matched cohort study of 14 patients with human epidermal growth factor receptor 2–positive breast cancer receiving sequential anthracycline and trastuzumab therapy, nested within the E valuation of M yocardial Changes During Br east A denocarcinoma Therapy to Detect C ardiotoxicity E arlier With MRI (EMBRACE-MRI) trial. Among patients who developed cardiotoxicity and were treated with heart failure therapy, we compared those who had trastuzumab therapy interrupted to a matched cohort who continued trastuzumab therapy. By a median of 2.5 years of follow-up, no significant differences were present between the groups in the proportion with magnetic resonance imaging–measured left ventricular ejection fraction < 40%, magnetic resonance imaging–measured left ventricular volumes, left ventricular ejection fraction, edema, fibrotic markers, cardiopulmonary fitness, or quality of life. La question de savoir s’il est sûr de poursuivre le traitement par un médicament ciblant le récepteur 2 du facteur de croissance épidermique humain (HER2) en présence d’une légère cardiotoxicité chez la femme demeure controversée. Nous avons réalisé une étude de cohortes appariées rétrospective auprès de 14 patientes atteintes d’un cancer du sein positif pour le HER2 qui recevaient un traitement séquentiel par l’anthracycline et le trastuzumab, dans le cadre du programme EMBRACE-MRI ( E valuation of M yocardial Changes During Br east A denocarcinoma Therapy to Detect C ardiotoxicity E arlier With MRI ). Parmi les patientes ayant développé une cardiotoxicité et ayant reçu un traitement pour l’insuffisance cardiaque, nous avons comparé celles dont le traitement par le trastuzumab a été interrompu à une cohorte appariée ayant poursuivi ce traitement. Après un suivi médian de 2,5 ans, aucune différence significative n’avait été observée entre les groupes en ce qui concerne le pourcentage de patientes dont la fraction d’éjection ventriculaire gauche était inférieure à 40 % à l’imagerie par résonance magnétique (IRM), le volume ventriculaire gauche à l’IRM, la fraction d’éjection ventriculaire gauche, l’œdème, les marqueurs fibrotiques, la bonne forme physique de l’appareil cardio-pulmonaire ou la qualité de vie.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Other design · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.917
Threshold uncertainty score0.738

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.019
GPT teacher head0.296
Teacher spread0.277 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designOther design
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2024
Admission routes2
Has abstractyes

Explore more

Same venueCJC OpenSame topicChemotherapy-induced cardiotoxicity and mitigationFrench-language works237,207